辅助治疗在IA期浆液性和透明细胞子宫癌中的作用:多机构汇总分析
该多机构回顾性研究纳入2004至2015年间6个北美中心414例因FIGO IA期浆液性、透明细胞或混合组织学子宫内膜癌行子宫切除术的患者,分析辅助治疗与观察对局部控制、无病生存和癌症特异性生存的影响,发现辅助放疗和化疗与更好的局部控制和无病生存相关,充分手术分期后观察可能合适。
要点
- 辅助阴道穹隆近距离放疗与局部控制改善相关(5年96% vs 84%,log-rank p=0.007)。
- 辅助化疗与局部控制改善相关(5年96% vs 84%,log-rank p=0.014)及无病生存改善相关(5年84% vs 69%,log-rank p=0.009)。
- 无辅助治疗患者中,充分手术分期者癌症特异性生存改善(100% vs 87%,log-rank p=0.022)。
核心结论
- 在IA期浆液性或透明细胞子宫癌中,辅助放疗和化疗与更好的局部控制和无病生存相关;对已行充分手术分期的患者,观察可能合适。
研究设计与样本
- 多机构回顾性队列研究,纳入6个北美中心2004至2015年间414例因FIGO IA期浆液性、透明细胞或混合组织学子宫内膜癌行子宫切除术的连续患者。
主要发现
- 术后管理包括观察(50%)、化疗和放疗(27%)、仅放疗(16%)和仅化疗(7%)。
- 178例接受放疗的患者中,接受体外放疗(EBRT)者占16%,阴道穹隆近距离放疗(VVB)者占56%,两者均接受者占28%。
- 无辅助治疗患者5年局部控制、无病生存和癌症特异性生存分别为82%(95%CI 74-88)、70%(62-78)和90%(82-94)。
- 无辅助治疗患者中,充分手术分期者癌症特异性生存改善(100% vs 87%(77-92),log-rank p=0.022)。
- 辅助VVB与局部控制改善相关(5年96%(91-99) vs 84%(76-89),log-rank p=0.007)及无病生存改善相关(5年79%(66-88) vs 71%(63-77),log-rank p=0.033)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As the optimal adjuvant management of stage IA serous or clear cell endometrial cancer is controversial, a multi-institutional review was conducted with the objective of evaluating the appropriateness of various strategies including observation. METHODS: Retrospective chart reviews for 414 consecutive patients who underwent hysterectomy for FIGO stage IA endometrial cancer with serous, clear cell or mixed histology between 2004 and 2015 were conducted in 6 North American centers. Time-to-event outcomes were analyzed by Kaplan-Meier estimates, log-rank test, univariable and multivariable cox proportional hazard regression models. RESULTS: Post-operative management included observation (50%), chemotherapy and radiotherapy (RT) (27%), RT only (16%) and chemotherapy only (7%). The 178 RT patients received external beam (EBRT, 16%), vaginal vault brachytherapy (VVB, 56%) or both (28%). Among patients without any adjuvant treatment, 5-year local control (LC), disease free survival (DFS) and cancer-specific survival (CSS) were 82% (95% confidence interval: 74-88), 70% (62-78) and 90% (82-94), respectively. CSS in patients without adjuvant treatment was improved with adequate surgical staging (100% vs. 87% (77-92), log-rank p=0.022). Adjuvant VVB was associated with improved LC (5-year 96% (91-99) vs. 84% (76-89), log-rank p=0.007) and DFS (5-year 79% (66-88) vs. 71% (63-77), log-rank p=0.033). Adjuvant chemotherapy was associated with better LC (5-year 96% (90-98) vs. 84% (77-89), log-rank p=0.014) and DFS (5-year 84% (74-91) vs. 69% (61-76), log-rank p=0.009). On multivariable analysis, adjuvant chemotherapy and VVB were associated with improved LC while adjuvant chemotherapy and age were significant for DFS. CONCLUSIONS: In stage IA serous or clear cell uterine cancer, adjuvant RT and chemotherapy were associated with better LC and DFS. Observation may be appropriate in patients who have had adequate surgical staging.
引用
- Qu XM, Velker VM, Leung E, et al. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. Gynecol Oncol. 2018. PMID: 29544706. doi:10.1016/j.ygyno.2018.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。